• Sweet's syndrome
• adverse drug reaction
• case/non‐case study
• drug safety

• Humans
• Sweet Syndrome/chemically induced
• Sweet Syndrome/epidemiology
• Sweet Syndrome/diagnosis
• Pharmacovigilance
• Female
• Middle Aged
• France/epidemiology
• Male
• Adult
• Aged
• Aged, 80 and over
• Databases, Factual/statistics & numerical data
• Young Adult
• Adolescent
• Adverse Drug Reaction Reporting Systems/statistics & numerical data
• Anti-Bacterial Agents/adverse effects
• Immunosuppressive Agents/adverse effects
• Antineoplastic Agents/adverse effects

• Common variable immunodeficiency
• Hypogammaglobulinemia
• Neutrophilic dermatoses
• Primary immunodeficiency
• Sweet’s syndrome

Sweet’s syndrome, also known as acute febrile neutrophilic dermatosis, is a rare disorder that typically presents with rapid appearance of tender skin lesions accompanied by fever and leukocytosis with neutrophilia. Its pathogenesis is not fully understood. The syndrome is generally classified into classical, malignancy-associated, and drug-induced categories, each of which has its specific characteristics. In this article, we present a case of classical Sweet’s syndrome in a woman who presented with an acute viral illness.

• inflammatory disorders
• neutrophilic dermatosis
• pregnancy associated disorders
• sweet syndrome
• therapy-systemic

• Clonality
• Hematological malignancy
• SNP array
• Sequencing
• Sweet's syndrome

Firstly described by Robert Douglas Sweet in 1964, febrile neutrophilic dermatosis is a disabling, not only cutaneous disorder, clinically characterised by fever and painful erythematous nodules, with a typical background of neutrophilia. Sweet’s syndrome (SS) is a chronic inflammatory reactive disorder of unknown cause and incompletely established pathogenesis, although an interplay between genetic and environmental factors, including infections, is likely to occur. A significant part of cases has been demonstrated to be linked with malignancies, especially in the hematologic setting. Because of the underlying disease and related therapeutic measures, SS may present atypical clinical course, whereas the response to treatment is strictly dependent on the concurrent hematologic disease. Herein we describe a case of a lady who had a refractory form of SS, resulted in a paraneoplastic cutaneous disease, and AML. Surprisingly, clinical remission of SS followed cytotoxic chemotherapy while hematologic disorder obtained a further complete response.

• Acute leukaemia
• Complete response
• Epirubicin
• Sweet syndrome

Sweet syndrome (acute, febrile, neutrophilic dermatosis) is characterized by the acute onset of an eruption of painful nodules or erythematous or violaceous plaques on the limbs, face and neck. These symptoms are accompanied by fever. The diagnostic features include histopathological findings of dermal neutrophilic infiltration without leukocytoclastic vasculitis or peripheral blood leukocytosis. Sweet syndrome is associated with infection, malignancies, autoimmune disease, pregnancy, and drugs. Patients with Sweet syndrome demonstrate a complete and rapid response to systemic steroid administration. Recently, a distinct variant of Sweet syndrome was reported, termed “histiocytoid Sweet syndrome”, in which the infiltration of myeloperoxidase-positive histiocytoid mononuclear cells are observed (in contrast to the infiltration of neutrophils). The other clinical features are similar to those of classic Sweet syndrome. Pediatric Sweet syndrome is uncommon, and the histiocytoid type is even rarer. To date, four cases of histiocytoid Sweet syndrome have been reported in children. Herein, we describe a case of histiocytoid Sweet syndrome in an otherwise healthy 10-year-old boy with no underlying systemic disease in whom non-steroidal, anti-inflammatory drug treatment was successful.

• Histiocytoid Sweet syndrome
• Myeloperoxidase

• Sweet’s syndrome

• Sweet syndrome
• drug-induced
• erythematous plaques
• fever
• leukocytosis
• neutrophilic dermatosis
• paraneoplastic phenomenon

• Arthropod bite reactions
• Autoinflammatory dermatitis
• Bullous pemphigoid
• Chronic urticaria
• Churg-Strauss disease
• Cutaneous lymphoid hyperplasia
• Dermal inflammatory diseases
• Drug eruptions
• Gyrate erythemas
• Hidradenitis suppurativa
• Hypereosinophilic syndrome
• Parasitic infestations
• Pigmented purpura
• Polymorphous light eruption
• Pyoderma gangrenosum
• Sweet syndrome
• Tumid lupus
• Urticarial vasculitis
• Viral exanthems
• Wells syndrome

Palisaded granulomatous dermatitis is an uncommon pathologic condition potentially associated with several disorders. These include drugs, inflammatory bowel disease, multiple myelomas, rheumatoid arthritis, and systemic lupus erythematosus. An illustrative case of a man with palisaded granulomatous dermatitis who subsequently developed ulcerative colitis is described, and the characteristics of other individuals with ulcerative colitis-associated palisaded granulomatous dermatitis are reviewed. PubMed was used to search the following terms: palisaded, interstitial, granulomatous, dermatitis, ulcerative colitis, and neutrophilic. Papers were obtained and references were reviewed. Ulcerative colitis-associated palisaded granulomatous dermatitis is uncommon. Palisaded granulomatous dermatitis-associated ulcerative colitis has been reported in four individuals. The palisaded granulomatous dermatitis appeared from six years prior to diagnosis to 19 years following diagnosis of the patient’s gastrointestinal disease. In addition to individual and grouped papular lesions on the elbows, the morphology of palisaded granulomatous dermatitis can also present as indurated linear plaques overlying the metacarpophalangeal (MCP) joints and proximal fingers. 

• dermatitis
• granulomatous
• palisaded
• ulcerative colitis

• histiocytoid Sweet’s
• myelodysplasia
• myelodysplastic
• sweet
• sweet’s
• syndrome

• Animals
• Disease Models, Animal
• Glycogen Synthase Kinase 3/deficiency
• Glycogen Synthase Kinase 3/metabolism
• Glycogen Synthase Kinase 3 beta
• Hematopoietic Stem Cells/enzymology
• Humans
• Leukemia, Myeloid, Acute/enzymology
• Leukemia, Myeloid, Acute/genetics
• Leukemia, Myeloid, Acute/therapy
• Mice, Transgenic
• Proto-Oncogene Proteins c-akt/metabolism
• Signal Transduction/physiology

• Canadian Institutes of Health Research

• Consultative dermatology
• Dermatology hospitalist
• Inpatient dermatology

• Cost Savings
• Dermatology/education
• Graft vs Host Disease/diagnosis
• Hospitalists
• Hospitalization
• Humans
• Immunocompromised Host
• Referral and Consultation
• Skin Diseases/diagnosis
• Skin Diseases/therapy

Throughout the history of mankind, infections have been the major cause of diseases. Over the last decades, not only the incidence of emerging infectious diseases have increased, but also tremendous strides have been made in understanding the biology of several pathogenic microorganisms. Helicobacter pylori (H. pylori) is a spiral-shaped, gram-negative bacterium, which infects over the half of the world’s population. H. pylori has been implicated in the pathogenesis of a number of gastrointestinal disorders. However, new researches have demonstrated that H. pylori is also involved in the pathogenesis of various extragastric diseases. The difference in the clinical outcome of H. pylori infection may be explained, at least in part, by host response to the infection and H. pylori virulence factors. It is obvious that as developments in the research on H. pylori spring up, an understanding of the pathophysiology of H. pylori infection will continue to be identified. Here in this review, we summarize the current knowledge about H. pylori and its association with inflammatory skin diseases.

• Helicobacter pylori
• Etiopathogenesis
• Skin diseases
• Inflammatory

Sweet’s syndrome, also referred to as acute febrile neutrophilic dermatosis, can either occur as an idiopathic disorder or associated with another condition, including cancer, or induced by exposure to a drug. Proton pump inhibitors selectively inhibit gastric parietal cell H+-K+-adenosine triphosphatase and are most commonly used for the treatment of gastroesophageal reflux disease.

Proton pump inhibitor-associated Sweet’s syndrome is described in a woman with recurrent breast cancer.

PubMed was used to search the following terms, separately and in combination: acute febrile neutrophilic dermatosis, breast cancer, malignancy, paraneoplastic, proton pump inhibitor, and Sweet’s syndrome. All papers were reviewed and relevant manuscripts, along with their reference citations, were evaluated.

Proton pump inhibitors have previously been associated with cutaneous adverse reactions including maculopapular rash, subacute cutaneous lupus erythematosus and toxic epidermal necrolysis. However, drug-induced Sweet’s syndrome has not been observed in patients receiving proton pump inhibitors. The reported woman developed Sweet’s syndrome after initial exposure and subsequent repeat challenge to proton pump inhibitors; subsequent studies also observed recurrence of her breast cancer presenting as metastases to her stomach and bone.

Drug-induced Sweet’s syndrome has most commonly been associated with granulocyte colony stimulating factor in oncology patients. Malignancy-associated Sweet’s syndrome has been observed in patients with solid tumors, including breast cancer. Confirmation of proton pump inhibitor-induced Sweet’s syndrome, by repeat challenge with another medication in the same class of drug, was observed in a woman with breast cancer; although the subsequent discovery of recurrent breast cancer presenting as gastric mucosa and vertebral metastases also raises the possibility of concurrent paraneoplastic Sweet’s syndrome, her Sweet’s syndrome symptoms and lesions resolved without recurrence while her recurrent metastatic visceral malignancy persisted. In summary, medication-associated Sweet’s syndrome can occur in oncology patients and proton pump inhibitors should be added to the list of medications associated with the potential to cause drug-induced Sweet’s syndrome.

• Sweet
• acute
• breast
• cancer
• dermatosis
• esomeprazole
• febrile
• inhibitor
• neutrophilic
• omeprazole
• proton
• pump
• syndrome

• Drug
• eruptions
• medications
• reactions
• skin

Sweet's syndrome is characterized by erythematous tender nodules and plaques over face and extremities. Fever, leukocytosis with neutrophilia, and a neutrophilic infiltrate in the dermis are characteristic features. Neutrophilic dermatosis of dorsal hands is a rare localized variant of Sweet's syndrome occurring predominantly over dorsa of hands. Various degrees of vascular damage may be observed on histopathology of these lesions. Both Sweet's syndrome and its dorsal hand variant have been reported in association with malignancies, inflammatory bowel diseases, and drugs. We report a patient with neutrophilic dermatoses of dorsal hands associated with erythema nodosum. He showed an excellent response to corticosteroids and dapsone.

• Neutrophilic dermatosis of dorsal hands
• Sweet's syndrome
• vasculitis

• Administration, Intravenous
• Adrenal Cortex Hormones/administration & dosage
• Adult
• Anemia/etiology
• Anti-Bacterial Agents/administration & dosage
• Biopsy
• Delayed Diagnosis
• Drug Administration Schedule
• Dyspnea/etiology
• Fatal Outcome
• Fever/etiology
• Humans
• Male
• Multiple Organ Failure/etiology
• Multiple Organ Failure/pathology
• Neutrophils/pathology
• Skin/pathology
• Sweet Syndrome/complications
• Sweet Syndrome/diagnosis
• Sweet Syndrome/drug therapy
• Sweet Syndrome/pathology

• Acute febrile neutrophilic dermatosis
• FMS-related tyrosine kinase-3
• Myelodysplastic syndrome
• Neutrophilic dermatosis
• −5/del(5q)

Neutrophilic dermatoses are a spectrum of autoinflammatory skin disorders that are characterized by extensive infiltration of neutrophils into the epidermis and dermis. The underlining biological pathways that are responsible for this heterogeneous group of cutaneous diseases have remained elusive. However, recent work from our laboratory and other groups has shown that missense mutations in Ptpn6, which encodes for the non-receptor protein tyrosine phosphatase Src homology region 2 (SH2) domain-containing phosphatase-1 (SHP-1), results in a skin disease with many of the major histopathological and clinical features that encompass neutrophilic dermatoses in humans. In particular, we found that loss-of-function mutation in Ptpn6 results in unremitting footpad swelling, suppurative inflammation, and neutrophilia. Dysregulated wound healing responses were discovered to contribute to chronic inflammatory skin disease in SHP-1 defective mice and genetic abrogation of interleukin-1 receptor (IL-1R) protected mice from cutaneous inflammation, suggesting that IL-1-mediated events potentiate disease. Surprisingly, inflammasome activation and IL-1β-mediated events were dispensable for Ptpn6^spin-mediated footpad disease. Instead, RIP1-mediated regulation of IL-1α was identified to be the major driver of inflammation and tissue damage.

• NOD-like receptor
• Ptpn6
• RIP1
• RIP3
• SHP-1
• caspase-1
• inflammasome
• inflammation
• interleukin
• neutrophilic dermatosis

• Dermatology
• Gastroenterology

• MDS
• MPD
• Sweet syndrome
• drug-induced Sweet syndrome
• malignancy-associated Sweet syndrome
• myelodysplastic syndrome
• myeloproliferative disorder
• treatment